Unicancer

This study tests whether adding targeted radiation (stereotactic radiosurgery) to a three-drug combination (binimetinib, encorafenib, pembrolizumab) helps control melanoma that has spread to the brain. It includes 10 adults with a specific gene mutation (BRAF V600). The main goal…

This study tests whether adding radiation to a standard immunotherapy-plus-chemotherapy regimen can help people with advanced non-small cell lung cancer live longer. About 327 participants will receive either the triple combination or standard treatment. The goal is to improve ov…

This study tests whether the drug atezolizumab can help keep bladder cancer from coming back after chemo-radiation therapy. It is for people with muscle-invasive bladder cancer who cannot or choose not to have their bladder removed. The goal is to control the disease and avoid re…

This phase 3 study compares two standard first treatments for women with ER+/HER2- breast cancer that has spread to organs like the liver or lungs. One group receives chemotherapy, while the other gets hormone therapy combined with a targeted drug called abemaciclib. The goal is …

This study tests whether adding a high-dose, precise type of radiation called SBRT to standard treatments (like hormone therapy or chemotherapy) can delay cancer progression in people with solid tumors that have spread to 1 to 5 spots in the bones. It includes adults up to age 75…

This study tests whether the drug regorafenib can stop or slow the growth of bone sarcomas that have spread to other parts of the body. About 163 patients with advanced osteosarcoma, Ewing sarcoma, chondrosarcoma, or chordoma will receive either regorafenib or a placebo. The main…

This study looks at whether women aged 50 and older with a very low-risk type of early breast cancer (called DCIS) can avoid radiation therapy after lumpectomy. The goal is to see if the cancer stays away without radiation, reducing unnecessary treatment and side effects. About 2…

This trial tests whether adding the drug mifamurtide to standard chemotherapy after surgery helps people with high-risk osteosarcoma (a type of bone cancer) live longer without the cancer coming back. The study includes 60 patients aged 2 to 50 with newly diagnosed, aggressive os…

This study tests whether adding the drug tucatinib to two standard breast cancer drugs (pertuzumab and trastuzumab) can help people with HER2-positive breast cancer that has spread to the brain. It includes 53 adults whose cancer progressed only in the brain after local treatment…

This study screens people with HR-positive, HER2-low metastatic breast cancer who are taking a CDK4/6 inhibitor. If a blood test still finds cancer DNA after one month, they receive the targeted drug trastuzumab deruxtecan (T-DXd). The goal is to see if T-DXd can delay cancer gro…

This study tests whether the drug durvalumab can help keep cancer from growing in frail patients with limited-stage small cell lung cancer who have already completed chemotherapy and radiation. About 100 participants will receive durvalumab every 4 weeks. The goal is to see if th…

This large international study is testing whether a personalized breast cancer screening plan—based on each woman's individual risk factors—works better than the standard one-size-fits-all approach. Over 53,000 women aged 40-70 are being followed for 4 years of different screenin…